227 related articles for article (PubMed ID: 21126020)
1. Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents.
Kumar K; Awasthi D; Lee SY; Zanardi I; Ruzsicska B; Knudson S; Tonge PJ; Slayden RA; Ojima I
J Med Chem; 2011 Jan; 54(1):374-81. PubMed ID: 21126020
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and evaluation of novel 2,5,6-trisubstituted benzimidazoles targeting FtsZ as antitubercular agents.
Park B; Awasthi D; Chowdhury SR; Melief EH; Kumar K; Knudson SE; Slayden RA; Ojima I
Bioorg Med Chem; 2014 May; 22(9):2602-12. PubMed ID: 24726304
[TBL] [Abstract][Full Text] [Related]
3. SAR studies on trisubstituted benzimidazoles as inhibitors of Mtb FtsZ for the development of novel antitubercular agents.
Awasthi D; Kumar K; Knudson SE; Slayden RA; Ojima I
J Med Chem; 2013 Dec; 56(23):9756-70. PubMed ID: 24266862
[TBL] [Abstract][Full Text] [Related]
4. Identification of TB-E12 as a novel FtsZ inhibitor with anti-tuberculosis activity.
Lin Y; Zhang H; Zhu N; Wang X; Han Y; Chen M; Jiang J; Si S
Tuberculosis (Edinb); 2018 May; 110():79-85. PubMed ID: 29779778
[TBL] [Abstract][Full Text] [Related]
5. Molecular dynamics analysis of the effects of GTP, GDP and benzimidazole derivative on structural dynamics of a cell division protein FtsZ from
Hakeem S; Singh I; Sharma P; Uppal A; Khajuria Y; Verma V; Uversky VN; Chandra R
J Biomol Struct Dyn; 2019 Oct; 37(16):4361-4373. PubMed ID: 30466358
[TBL] [Abstract][Full Text] [Related]
6. Computational studies of the properties and activities of selected trisubstituted benzimidazoles as potential antitubercular drugs inhibiting MTB-FtsZ polymerization.
Akinpelu OI; Lawal MM; Kumalo HM; Mhlongo NN
J Biomol Struct Dyn; 2022 Mar; 40(4):1558-1570. PubMed ID: 33021149
[TBL] [Abstract][Full Text] [Related]
7. An efficient and facile green synthesis of bisindole methanes as potential Mtb FtsZ inhibitors.
Khadkikar P; Goud NS; Mohammed A; Ramamoorthy G; Ananthathatmula R; Doble M; Rizvi A; Banerjee S; Ravi A; Alvala M
Chem Biol Drug Des; 2018 Dec; 92(6):1933-1939. PubMed ID: 30003661
[TBL] [Abstract][Full Text] [Related]
8. A novel quinoline derivative that inhibits mycobacterial FtsZ.
Mathew B; Ross L; Reynolds RC
Tuberculosis (Edinb); 2013 Jul; 93(4):398-400. PubMed ID: 23647650
[TBL] [Abstract][Full Text] [Related]
9. A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis.
Knudson SE; Awasthi D; Kumar K; Carreau A; Goullieux L; Lagrange S; Vermet H; Ojima I; Slayden RA
PLoS One; 2014; 9(4):e93953. PubMed ID: 24736743
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore based approach to screen and evaluate novel Mycobacterium cell division inhibitors targeting FtsZ - A modelling and experimental study.
Mitra K; Chadha A; Doble M
Eur J Pharm Sci; 2019 Jul; 135():103-112. PubMed ID: 31034983
[TBL] [Abstract][Full Text] [Related]
11. 2-Alkoxycarbonylaminopyridines: inhibitors of Mycobacterium tuberculosis FtsZ.
White EL; Suling WJ; Ross LJ; Seitz LE; Reynolds RC
J Antimicrob Chemother; 2002 Jul; 50(1):111-4. PubMed ID: 12096015
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship studies on 2,5,6-trisubstituted benzimidazoles targeting
Haranahalli K; Tong S; Kim S; Awwa M; Chen L; Knudson SE; Slayden RA; Singleton E; Russo R; Connell N; Ojima I
RSC Med Chem; 2021 Jan; 12(1):78-94. PubMed ID: 34046600
[TBL] [Abstract][Full Text] [Related]
13. Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents.
Huang Q; Kirikae F; Kirikae T; Pepe A; Amin A; Respicio L; Slayden RA; Tonge PJ; Ojima I
J Med Chem; 2006 Jan; 49(2):463-6. PubMed ID: 16420032
[TBL] [Abstract][Full Text] [Related]
14. Identification of anti-tuberculosis agents that target the cell-division protein FtsZ.
Lin Y; Zhu N; Han Y; Jiang J; Si S
J Antibiot (Tokyo); 2014 Sep; 67(9):671-6. PubMed ID: 24984796
[TBL] [Abstract][Full Text] [Related]
15. MoS
Raghu MS; Pradeep Kumar CB; Prasad KNN; Prashanth MK; Kumarswamy YK; Chandrasekhar S; Veeresh B
ACS Comb Sci; 2020 Oct; 22(10):509-518. PubMed ID: 32806898
[TBL] [Abstract][Full Text] [Related]
16. Antituberculosis: synthesis and antimycobacterial activity of novel benzimidazole derivatives.
Keng Yoon Y; Ashraf Ali M; Choon TS; Ismail R; Chee Wei A; Suresh Kumar R; Osman H; Beevi F
Biomed Res Int; 2013; 2013():926309. PubMed ID: 24381946
[TBL] [Abstract][Full Text] [Related]
17. Benzimidazole-based compounds kill Mycobacterium tuberculosis.
Gong Y; Somersan Karakaya S; Guo X; Zheng P; Gold B; Ma Y; Little D; Roberts J; Warrier T; Jiang X; Pingle M; Nathan CF; Liu G
Eur J Med Chem; 2014 Mar; 75():336-53. PubMed ID: 24556148
[TBL] [Abstract][Full Text] [Related]
18. Benzimidazoquinazolines as new potent anti-TB chemotypes: Design, synthesis, and biological evaluation.
Jadhavar PS; Patel KI; Dhameliya TM; Saha N; Vaja MD; Krishna VS; Sriram D; Chakraborti AK
Bioorg Chem; 2020 Jun; 99():103774. PubMed ID: 32224336
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and molecular docking studies of imidazole and benzimidazole linked ethionamide derivatives as inhibitors of InhA and antituberculosis agents.
Raghu MS; Pradeep Kumar CB; Yogesh Kumar K; Prashanth MK; Alshahrani MY; Ahmad I; Jain R
Bioorg Med Chem Lett; 2022 Mar; 60():128604. PubMed ID: 35123004
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of antimycobacterial activity of new benzimidazole aminoesters.
Yoon YK; Ali MA; Wei AC; Choon TS; Ismail R
Eur J Med Chem; 2015 Mar; 93():614-24. PubMed ID: 24996257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
